Olaf Panknin

USPTO Granted Patents = 16 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 11 (Patent Applications = 17)

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

16 out of 378

Bayer Pharma Aktiengesellschaft

patents

2 out of 12,157

Bayer Aktiengesellschaft

patents

1 out of 155

Deutsches Krebsforschungszentrum

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12478696 - Gadolinium chelate compounds for use in magnetic resonance imaging (2025-11-25),

2. 11814369 - High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging (2023-11-14),

3. 11491245 - Gadolinium chelate compounds for use in magnetic resonance imaging (2022-11-08),

4. 11427578 - Substituted pyrrolopyridine-derivatives (2022-08-30),

5. 11311520 - Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors (2022-04-26),

6. 10975060 - High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging (2021-04-13),

7. 10919862 - Fused imidazoles as mIDH1 inhibitors (2021-02-16),

8. 10722601 - Gadolinium chelate compounds for use in magnetic resonance imaging (2020-07-28),

9. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

10. 10414734 - 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors (2019-09-17),

11. 10370339 - N-Methylbenzimidazoles as mIDH1 inhibitors (2019-08-06),

12. 10179123 - 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors (2019-01-15),

13. 10137209 - Gadolinium chelate compounds for use in magnetic resonance imaging (2018-11-27),

14. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors (2018-11-27),

15. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

Certainly! Here is the article about inventor Olaf Panknin:

Title: Olaf Panknin: A Trailblazer in Innovation

Introduction:

Olaf Panknin, a renowned inventor based in Berlin, DE, has captured the essence of relentless pursuit of innovation in the world of inventions. With an impressive portfolio of 15 patents under his belt, Panknin's commitment to creating a better future through groundbreaking technology places him as a standout figure in the industry.

Latest Patents:

Panknin's latest patents showcase his groundbreaking work in the field of medical imaging. One notable invention includes the development of high relaxivity gadolinium chelate compounds for use in magnetic resonance imaging. These novel compounds promise enhanced imaging capabilities, revolutionizing the way healthcare professionals diagnose and treat patients.

Career Highlights:

Throughout his illustrious career, Panknin has made significant contributions while working at Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His innovative spirit and dedication to pushing the boundaries of technological advancements have earned him a reputable status within the industry.

Collaborations:

Panknin has collaborated with esteemed colleagues such as Katja Zimmermann and Roland Neuhaus, further enriching his innovative projects with diverse expertise and perspectives. Together, they have paved the way for cutting-edge developments that continue to shape the landscape of inventions.

Conclusion:

Olaf Panknin's unwavering passion for innovation and his ceaseless efforts to drive positive change through technology have set a new standard in the world of inventions. His work serves as an inspiration for the next generation of inventors, highlighting the transformative power of creativity and perseverance in creating a brighter future for all.

This text is generated by artificial intelligence and may not be accurate.